Stempeutics weighs Japan tie-up for stem cell therapy
This article was originally published in Scrip
Executive Summary
Japan continues to attract interest in the area of regenerative medicine. Indian firm Stempeutics Research now says it is eyeing collaboration opportunities for its stem-cell based drug, Stempeucel, initially targeted for the treatment of critical limb ischemia.
You may also be interested in...
India Clears Off-The-Shelf Stem Cell Therapy for Buerger's
Stempeutics Research has been granted limited approval to make and sell the first allogeneic cell therapy product for Buerger’s Disease in India. The stem cell therapy, which was granted orphan drug designation by the EMA last year, may hold potential in certain additional indications as well.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.